Canaccord Genuity Maintains Buy on TransMedics Group, Raises Price Target to $120
Benzinga Newsdesk 1 day ago
Analyst RatingsNewsPrice Target
Canaccord Genuity analyst Jason Mills maintains TransMedics Group (NASDAQ:TMDX) with a Buy and raises the price target from $95 to $120.
Canaccord Genuity analyst Jason Mills maintains TransMedics Group (NASDAQ:TMDX) with a Buy and raises the price target from $95 to $120.